Skip to main content Back to Top
Advertisement

2/12/2024

Lidocaine 5% Transdermal Patch

Products Affected - Description

    • Lidoderm transdermal patch, Endo Pharmaceuticals, 5%, 30 count, NDC 63481-0687-06 - discontinued
    • Lidocaine transdermal patch, Amneal, 5%, 30 count, NDC 65162-0791-08
    • Lidocaine transdermal patch, Par Pharmaceuticals, 5%, 30 count, NDC 00603-1880-16
    • Lidocaine transdermal patch, Teva, 5%, 30 count, NDC 00591-3525-30

Reason for the Shortage

    • Amneal did not provide a reason for the shortage.
    • Endo discontinued Lidoderm patches in January 2023.
    • Mylan has lidocaine 5% transdermal patches available.
    • Par did not provide a reason for the shortage.
    • Teva did not provide a reason for the shortage.

Available Products

    • Lidocaine transdermal patch, Mylan (Viatris), 5%, 30 count, NDC 00378-9055-93

Estimated Resupply Dates

    • Amneal has lidocaine 5% transdermal patches in 30 count boxes on allocation.
    • Par has lidocaine 5% transdermal patches in 30 count boxes in limited supply.
    • Teva has lidocaine 5% transdermal patches in 30 count boxes on back order and the company estimates a release date in mid-February 2024.

Updated

Updated February 12, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created November 9, 2022 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.